Pathogenesis of acute respiratory illness caused by human parainfluenza viruses

Current Opinion in Virology

Volumn 2, Issue 3, 2012, Pages 294-299

  Schomacker, Henrick ^a   Schaap Nutt, Anne ^a   Collins, Peter L ^a   Schmidt, Alexander C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ACUTE RESPIRATORY TRACT DISEASE; ADAPTIVE IMMUNITY; BRONCHIOLITIS; CYTOPATHOLOGY; DISEASE SEVERITY; EPITHELIUM CELL; EX VIVO STUDY; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; NONHUMAN; PARAINFLUENZA VIRUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TROPISM; VIRAL TROPISM; VIRUS GENOME; VIRUS REPLICATION;

BRONCHIOLITIS, VIRAL; CHILD, PRESCHOOL; CROUP; HUMANS; IMMUNE EVASION; IMMUNOCOMPROMISED HOST; INFANT; PARAMYXOVIRIDAE INFECTIONS; PNEUMONIA, VIRAL; RESPIRATORY MUCOSA; RESPIROVIRUS;

EID: 84862904731     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.02.001     Document Type: Review

References (80)

1. Cooney MK, Fox JP, Hall CE: The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975, 101:532-551. This article and related publications cover the results of the Seattle Virus Watch, which enrolled families between 1969 and 1974 and monitored infections caused by different viruses during childhood.
2. Welliver RC, Wong DT, Sun M, McCarthy N: Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 1986, 140:34-40. (Pubitemid 16075630)
3. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF: Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis 1997, 175:807-813. (Pubitemid 27142952)
4. Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ: Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001, 20:646-653. (Pubitemid 32652313)
5. Weinberg GA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffin MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG: Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009, 154:694-699. Between 2000 and 2004, the New Vaccine Surveillance Network enrolled 2798 children under 5 with febrile or acute respiratory illness and reported that 6.9% of the infections leading to hospitalization are caused by human parainfluenza viruses.
6. Forster J, Ihorst G, Rieger CH, Stephan V, Frank HD, Gurth H, Berner R, Rohwedder A, Werchau H, Schumacher M et al.: Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur J Pediatr 2004, 163:709-716. (Pubitemid 40064377)
7. Billaud G, Morfin F, Vabret A, Boucher A, Gillet Y, Crassard N, Galambrun C, Ferraris O, Legrand L, Aymard M et al.: Human parainfluenza virus type 4 infections: a report of 20 cases from 1998 to 2002. J Clin Virol 2005, 34:48-51. (Pubitemid 41125876)
8. Yea C, Cheung R, Collins C, Adachi D, Nishikawa J, Tellier R: The complete sequence of a human parainfluenzavirus 4 genome. Viruses 2009, 1:26-41.
9. Fairchok MP, Martin ET, Kuypers J, Englund JA: A prospective study of parainfluenza virus type 4 infections in children attending daycare. Pediatr Infect Dis J 2011, 30:714-716.
10. Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson LJ: Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997, 176:1423-1427. (Pubitemid 27518139)
11. Rihkanen H, Ronkko E, Nieminen T, Komsi KL, Raty R, Saxen H, Ziegler T, Roivainen M, Soderlund-Venermo M, Beng AL et al.: Respiratory viruses in laryngeal croup of young children. J Pediatr 2008, 152:661-665.
12. Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL: Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med 2011, 5:515-526.
13. Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC: Evaluation of two chimeric bovinehuman parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2011. This reference and reference [14] describe the results of clinical trials with live attenuated HPIV3 vaccine candidates in seronegative children. The safety and immunogenicity of three potential vaccines are discussed.
14. Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC: The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated,infectious, and immunogenic in infants and young children. Pediatr Infect Dis J 2011, 30:e186-e191.
15. Karron RA, Collins PL: Chapter 42. Parainfluenza viruses. In Fields Virology, vol 1. Edited by Knipe DM, Howley PM. Lippincott Williams & Wilkins; 2007:1497-1526.
16. Parrott RH, Vargosko A, Luckey A, Kim HW, Cumming C, Chanock R: Clinical features of infection with hemadsorption viruses. N Engl J Med 1959, 260:731-738.
17. Russell KF, Liang Y, O'Gorman K, Johnson DW, Klassen TP: Glucocorticoids for croup. Cochrane Database Syst Rev 2011. CD001955.
18. Bjornson C, Russell KF, Vandermeer B, Durec T, Klassen TP, Johnson DW: Nebulized epinephrine for croup in children. Cochrane Database Syst Rev 2011:CD006619.
19. Campbell AP, Chien JW, Kuypers J, Englund JA, Wald A, Guthrie KA, Corey L, Boeckh M: Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010, 201:1404-1413.
20. Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT: Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1520-1527.
21. Henrickson KJ: Parainfluenza viruses. Clin Microbiol Rev 2003, 16:242-264.
22. Rochat S, Komada H, Kolakofsky D: Loss of V protein expression in human parainfluenza virus type 1 is not a recent event. Virus Res 1992, 24:137-144.
23. Durbin AP, McAuliffe JM, Collins PL, Murphy BR: Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999, 261:319-330. (Pubitemid 29431784)
24. Galinski MS, Troy RM, Banerjee AK: RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3. Virology 1992, 186:543-550.
25. Goodbourn S, Didcock L, Randall RE: Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000, 81:2341-2364.
26. Levy DE, Garcia-Sastre A: The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001, 12:143-156. (Pubitemid 32590836)
27. Katze MG, He Y, Gale M Jr: Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002, 2:675-687. (Pubitemid 37328725)
28. Takaoka A, Yanai H: Interferon signalling network in innate defence. Cell Microbiol 2006, 8:907-922. (Pubitemid 43670834)
29. Goodbourn S, Randall RE: The regulation of type I interferon production by paramyxoviruses. J Interferon Cytokine Res 2009, 29:539-547.
30. Horvath CM: Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem 2004, 271:4621-4628.
31. Gotoh B, Komatsu T, Takeuchi K, Yokoo J: Paramyxovirus strategies for evading the interferon response. Rev Med Virol 2002, 12:337-357. (Pubitemid 35334421)
32. Curran J, Kolakofsky D: Scanning independent ribosomal initiation of the Sendai virus Y proteins in vitro and in vivo. EMBO J 1989, 8:521-526. (Pubitemid 19274972)
33. Boeck R, Curran J, Matsuoka Y, Compans R, Kolakofsky D: The parainfluenza virus type 1 P/C gene uses a very efficient GUG codon to start its C0 protein. J Virol 1992, 66:1765-1768.
34. Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ: Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 2006, 352:61-73. (Pubitemid 44164412)
35. Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL et al.: Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 2008, 82:8965-8977.
36. Boonyaratanakornkit J, Bartlett E, Schomacker H, Surman S, Akira S, Bae YS, Collins P, Murphy B, Schmidt A: The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R. J Virol 2011, 85:1495-1506.
37. Schomacker H, Hebner RM, Boonyaratanakornkit J, Surman S, Amaro-Carambot E, Collins PL, Schmidt AC: The C proteins of Human Parainfluenza Virus Type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome. PLoS One 2012, 7:e28382.
38. Boonyaratanakornkit JB, Bartlett EJ, Amaro-Carambot E, Collins PL, Murphy BR, Schmidt AC: The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection. J Virol 2009, 83:1892-1910. This publication shows how gene expression patterns differ between a parainfluenza virus that is able to suppress IFN induction and signaling (WT HPIV1) and a mutant that does not express an IFN antagonist protein (P(C-) HPIV1).
39. Malur AG, Hoffman MA, Banerjee AK: The human parainfluenza virus type 3 (HPIV 3) C protein inhibits viral transcription. Virus Res 2004, 99:199-204. (Pubitemid 38121669)
40. Caignard G, Komarova AV, Bourai M, Mourez T, Jacob Y, Jones LM, Rozenberg F, Vabret A, Freymuth F, Tangy F et al.: Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. PLoS Pathog 2009, 5:e1000587.
41. Malur AG, Chattopadhyay S, Maitra RK, Banerjee AK: Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein. J Virol 2005, 79:7877-7882. (Pubitemid 40756823)
42. Poole E, He B, Lamb RA, Randall RE, Goodbourn S: The V proteins of Simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002, 303:33-46. (Pubitemid 36027163)
43. Parisien JP, Lau JF, Rodriguez JJ, Sullivan BM, Moscona A, Parks GD, Lamb RA, Horvath CM: The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 2001, 283:230-239. (Pubitemid 32881170)
44. Schaap-Nutt A, D'Angelo C, Scull MA, Amaro-Carambot E, Nishio M, Pickles RJ, Collins PL, Murphy BR, Schmidt AC: Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in nonhuman primates. Virology 2010, 397:285-298.
45. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE: The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 2004, 101:17264-17269. (Pubitemid 39627808)
46. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R, Goodbourn S: mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007, 359:190- 200.
47. Lu LL, Puri M, Horvath CM, Sen GC: Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem 2008, 283:14269-14276.
48. Nishio M, Ohtsuka J, Tsurudome M, Nosaka T, Kolakofsky D: Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness. J Virol 2008, 82:6130-6138. (Pubitemid 351875095)
49. Andrejeva J, Young DF, Goodbourn S, Randall RE: Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol 2002, 76:2159-2167.Here, the authors showed time that HPIV2 V proteins promote the degradation of Stat2, in contrast to the SV5 V protein, which promotes the degradation of Stat1.
50. Schaap-Nutt A, D'Angelo C, Amaro-Carambot E, Nolan SM, Davis S, Wise SM, Higgins C, Bradley K, Kim O, Mayor R et al.: Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. Virology 2010, 406:65-79.
51. Schaap-Nutt A, Higgins C, Amaro-Carambot E, Nolan SM, D'Angelo C, Murphy BR, Collins PL, Schmidt AC: Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. J Virol 2011, 85:4007-4019.
52. Nishio M, Tsurudome M, Ito M, Ito Y: Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect. J Virol 2005, 79:14756-14768. (Pubitemid 41636274)
53. Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, Pickles RJ: Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005, 79:1113-1124. The first publication exploring HPIV tropism using the HAE model, establishing that HPIV3 only infects the superficial ciliated cells with minimal cytopathology.
54. Schaap-Nutt A, Scull MA, Schmidt AC, Murphy BR, Pickles RJ: Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 2010, 28:2788-2798.
55. Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, Murphy BR, Pickles RJ: Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J Virol 2008, 82:8059-8070.
56. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015. (Pubitemid 29019052)
57. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC: Limited entry of adenovirus vectors into welldifferentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998, 72:6014-6023. (Pubitemid 28283390)
58. Le Nouen C, Munir S, Losq S, Winter CC, McCarty T, Stephany DA, Holmes KL, Bukreyev A, Rabin RL, Collins PL et al.: Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology 2009, 385:169-182.
59. Palermo LM, Porotto M, Yokoyama CC, Palmer SG, Mungall BA, Greengard O, Niewiesk S, Moscona A: Human parainfluenza virus infection of the airway epithelium: viral hemagglutininneuraminidase regulates fusion protein activation and modulates infectivity. J Virol 2009, 83:6900-6908.
60. Downham MA, Gardner PS, McQuillin J, Ferris JA: Role of respiratory viruses in childhood mortality. Br Med J 1975, 1:235-239.
61. Delage G, Brochu P, Pelletier M, Jasmin G, Lapointe N: Giant-cell pneumonia caused by parainfluenza virus. J Pediatr 1979, 94:426-429. (Pubitemid 9111090)
62. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J: Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970, 23:7-18.
63. Jarvis WR, Middleton PJ, Gelfand EW: Parainfluenza pneumonia in severe combined immunodeficiency disease. J Pediatr 1979, 94:423-425. (Pubitemid 9111089)
64. Weintrub PS, Sullender WM, Lombard C, Link MP, Arvin A: Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia. Arch Pathol Lab Med 1987, 111:569-570. (Pubitemid 17085990)
65. Madden JF, Burchette JL Jr, Hale LP: Pathology of parainfluenza virus infection in patients with congenital immunodeficiency syndromes. Hum Pathol 2004, 35:594-603. (Pubitemid 38656945)
66. Crowe JE Jr, Williams JV: Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev 2003, 4:112-119.
67. Miyairi I, DeVincenzo JP: Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 2008, 21:686-703.
68. do Carmo Debur M, Raboni SM, Flizikowski FB, Chong DC, Persicote AP, Nogueira MB, Rosele LV, de Almeida SM, de Noronha L: Immunohistochemical assessment of respiratory viruses in necropsy samples from lethal non-pandemic seasonal respiratory infections. J Clin Pathol 2010, 63:930-934.
69. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS: The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007, 20:108-119. (Pubitemid 44967956)
70. Smith CB, Purcell RH, Bellanti JA, Chanock RM: Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966, 275:1145-1152. This article established that neutralizing mucosal antibodies are a good correlate of protection from HPIV infections and are more effective than neutralizing serum antibodies.
71. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL: Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 1987, 61:3416-3423. (Pubitemid 17152163)
72. Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM: Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 1988, 11:1-15.
73. Glezen WP, Frank AL, Taber LH, Kasel JA: Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984, 150:851-857. (Pubitemid 15182138)
74. El Feghaly RE, McGann L, Bonville CA, Branigan PJ, Suryadevera M, Rosenberg HF, Domachowske JB: Local production of inflammatory mediators during childhood parainfluenza virus infection. Pediatr Infect Dis J 2010, 29:e26-e31.
75. Gern JE, Martin MS, Anklam KA, Shen K, Roberg KA, Carlson- Dakes KT, Adler K, Gilbertson-White S, Hamilton R, Shult PA et al.: Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. Pediatr Allergy Immunol 2002, 13:386-393. (Pubitemid 36069949)
76. Hall CB, Douglas RG Jr, Simons RL, Geiman JM: Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr 1978, 93:28-32. (Pubitemid 8351863)
77. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A et al.: Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184:662-671.
78. Sumino KC, Walter MJ, Mikols CL, Thompson SA, Gaudreault- Keener M, Arens MQ, Agapov E, Hormozdi D, Gaynor AM, Holtzman MJ et al.: Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness. Thorax 2010, 65:639-644.
79. McNamara PS, Flanagan BF, Hart CA, Smyth RL: Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005, 191:1225-1232.
80. Utokaparch S, Marchant D, Gosselink JV, McDonough JE, Thomas EE, Hogg JC, Hegele RG: The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr Infect Dis J 2011, 30:e18-e23.